Karius utilizes advanced clinical metagenomics to enhance infectious disease diagnostics, focusing on the detection of microbial cell-free DNA (mcfDNA) in the bloodstream. This innovative approach allows for the identification of over 1,000 pathogens that can cause infections, providing critical genomic insights that facilitate timely and accurate diagnoses. The Karius Test is particularly beneficial for immunocompromised patients, who are at a higher risk for severe infections, by offering a non-invasive liquid biopsy alternative to traditional diagnostic methods.

The company employs sophisticated artificial intelligence (AI) and machine learning algorithms to analyze complex genomic data in real time. Their proprietary reference genome databases are continuously updated, ensuring that the diagnostic tools remain at the forefront of medical technology. Karius's commitment to refining its methodologies is evident in its extensive clinical studies and trials, which validate the effectiveness of its testing in various patient populations, including those with febrile neutropenia, pneumonia, and other opportunistic infections. This combination of genomics and AI positions Karius as a leader in the field of infectious disease diagnostics.

United States

Karius sees a world where infectious disease is no longer a major threat to human health.  The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions. 

Karius

Company Details